Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

OBJECTIVES: To examine the long-term survival outcome of dabrafenib in combination with trametinib in Chinese patients with unresectable or metastatic acral/cutaneous melanoma with BRAF-V600 mutation and to explore potential predictors of effectiveness. METHODS: This was a long-term follow-up of Chi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Lili, Ding, Ya, Bai, Xue, Sheng, Xinan, Dai, Jie, Chi, Zhihong, Cui, Chuanliang, Kong, Yan, Fan, Yun, Xu, Yanjun, Wang, Xuan, Tang, Bixia, Lian, Bin, Yan, Xieqiao, Li, Siming, Zhou, Li, Wei, Xiaoting, Li, Caili, Guo, Jun, Zhang, Xiaoshi, Si, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422804/
https://www.ncbi.nlm.nih.gov/pubmed/34504796
http://dx.doi.org/10.3389/fonc.2021.720044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422804/
https://www.ncbi.nlm.nih.gov/pubmed/34504796
http://dx.doi.org/10.3389/fonc.2021.720044

Ejemplares similares